Oncology

Yesterday, drug manufacturer Bristol-Myers Squibb announced that the FDA has approved the combination nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following a fluoropyrimidine, oxaliplatin, or irinotecan-based chemotherapy treatment.

Only 34% of patients with chronic myeloid leukemia (CML) in a small study in China were likely to be positive about attempting treatment-free remission.

Researchers have recently discovered a new type of small-cell lung cancer, and the discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.